RU2747536C2 - Новая терапия транстиретин-ассоциированного амилоидоза - Google Patents

Новая терапия транстиретин-ассоциированного амилоидоза Download PDF

Info

Publication number
RU2747536C2
RU2747536C2 RU2017119539A RU2017119539A RU2747536C2 RU 2747536 C2 RU2747536 C2 RU 2747536C2 RU 2017119539 A RU2017119539 A RU 2017119539A RU 2017119539 A RU2017119539 A RU 2017119539A RU 2747536 C2 RU2747536 C2 RU 2747536C2
Authority
RU
Russia
Prior art keywords
ttr
tolcapone
comt inhibitor
inhibitor
pharmaceutically acceptable
Prior art date
Application number
RU2017119539A
Other languages
English (en)
Russian (ru)
Other versions
RU2017119539A (ru
RU2017119539A3 (OSRAM
Inventor
КАСАДО Марк СЕНТЕЯС
БОРОНАТ Рауль ИНСА
БОЛАНЬО Нурия РЕЙГ
БАТАЛЛА Нурия ГАВАЛЬДА
Original Assignee
Сом Инновэйшн Биотек, С.Л.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47076222&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2747536(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Сом Инновэйшн Биотек, С.Л. filed Critical Сом Инновэйшн Биотек, С.Л.
Publication of RU2017119539A publication Critical patent/RU2017119539A/ru
Publication of RU2017119539A3 publication Critical patent/RU2017119539A3/ru
Application granted granted Critical
Publication of RU2747536C2 publication Critical patent/RU2747536C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/603—Salicylic acid; Derivatives thereof having further aromatic rings, e.g. diflunisal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
RU2017119539A 2011-10-24 2012-10-23 Новая терапия транстиретин-ассоциированного амилоидоза RU2747536C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11382326 2011-10-24
ES11382326.4 2011-10-24

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2014114930A Division RU2623062C2 (ru) 2011-10-24 2012-10-23 Новая терапия транстиретин-ассоциированного амилоидоза

Publications (3)

Publication Number Publication Date
RU2017119539A RU2017119539A (ru) 2018-11-09
RU2017119539A3 RU2017119539A3 (OSRAM) 2020-06-29
RU2747536C2 true RU2747536C2 (ru) 2021-05-06

Family

ID=47076222

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2017119539A RU2747536C2 (ru) 2011-10-24 2012-10-23 Новая терапия транстиретин-ассоциированного амилоидоза
RU2014114930A RU2623062C2 (ru) 2011-10-24 2012-10-23 Новая терапия транстиретин-ассоциированного амилоидоза

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2014114930A RU2623062C2 (ru) 2011-10-24 2012-10-23 Новая терапия транстиретин-ассоциированного амилоидоза

Country Status (19)

Country Link
US (5) US9610270B2 (OSRAM)
EP (1) EP2770988B1 (OSRAM)
JP (1) JP6068484B2 (OSRAM)
KR (1) KR102017354B1 (OSRAM)
CN (1) CN103889407B (OSRAM)
AU (2) AU2012327275B2 (OSRAM)
BR (1) BR112014009322B1 (OSRAM)
CA (1) CA2852808C (OSRAM)
CL (1) CL2014000893A1 (OSRAM)
CY (1) CY1118151T1 (OSRAM)
ES (1) ES2593038T3 (OSRAM)
IL (1) IL231907B (OSRAM)
MX (2) MX385516B (OSRAM)
PL (1) PL2770988T3 (OSRAM)
PT (1) PT2770988T (OSRAM)
RU (2) RU2747536C2 (OSRAM)
SG (2) SG10201609933WA (OSRAM)
WO (1) WO2013060668A1 (OSRAM)
ZA (1) ZA201402546B (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103889407B (zh) * 2011-10-24 2017-03-15 索姆创新生物技术公司 用于甲状腺素运载蛋白相关的淀粉样变性的疗法
DK3185957T3 (da) * 2014-08-29 2022-08-29 Alnylam Pharmaceuticals Inc Patisiran til anvendelse ved behandlingen af transthyretin-medieret amyloidosis
EP3275433A1 (en) * 2016-07-29 2018-01-31 Som Innovation Biotech S.L. Sustained release composition comprising micronized tolcapone
MX2020009548A (es) * 2018-03-12 2021-01-08 Corino Therapeutics Inc Terapia combinada para la amiloidosis ttr.
CA3141998A1 (en) * 2019-05-31 2020-12-03 Plex Pharmaceuticals, Inc. Pharmacological agents for treating protein aggregation diseases of the eye
CN114324693B (zh) * 2022-01-14 2023-01-13 大连博源医学科技有限公司 一种血液中转甲状腺素蛋白(ttr)四聚体浓度测定的预处理方法和检测方法
JP2025536853A (ja) * 2022-10-10 2025-11-07 コリノ セラピューティクス，インク． 放出調節トルカポン処方剤

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005112913A1 (en) * 2004-05-20 2005-12-01 The Scripps Research Institute Transthyretin stabilization

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744368A (en) 1993-11-04 1998-04-28 Research Foundation Of State University Of New York Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR)
AU5727798A (en) 1996-12-23 1998-07-17 Texas A & M University, The Anti-amyloidogenic agents
FI20002044A0 (fi) * 2000-09-15 2000-09-15 Orion Yhtymae Oyj Comt-entsyymiä estäviä naftaleenijohdannaisia
CA2440293C (en) 2001-03-15 2012-01-24 Proteotech, Inc. Catechins for the treatment of fibrillogenesis in alzheimer's disease, parkinson's disease, systemic aa amyloidosis, and other amyloid disorders
JP2006510722A (ja) 2002-01-29 2006-03-30 プロテミックス コーポレイション リミティド 細胞障害性タンパク質コンフォーマーの抑制
US20040175382A1 (en) * 2003-03-06 2004-09-09 Schafer Peter H. Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
CN1921856A (zh) * 2004-02-20 2007-02-28 诺瓦提斯公司 用于治疗神经变性疾病和认知障碍的dpp－iv抑制剂
BRPI0507905A (pt) 2004-02-20 2007-07-10 Novartis Ag uso de compostos orgánicos
ES2339790T3 (es) 2004-08-30 2010-05-25 Seo Hong Yoo Efecto neuroprotector de udca solubilizado en modelo isquemico focal.
GB2429645A (en) 2006-03-10 2007-03-07 Sekhsaria Chemicals Ltd Solid pharmaceutical composition comprising a COMT inhibitor, a starch and a wetting agent
US20120016037A1 (en) 2006-07-24 2012-01-19 Frank Toppo Method for prevention and treatment of Alzheimers
GB0718718D0 (en) 2007-09-25 2007-11-07 Pentraxin Therapeutics Ltd Compound and use thereof
DE102010010572A1 (de) 2010-03-08 2011-09-08 Mahle International Gmbh Trockenseparator
CN103889407B (zh) * 2011-10-24 2017-03-15 索姆创新生物技术公司 用于甲状腺素运载蛋白相关的淀粉样变性的疗法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005112913A1 (en) * 2004-05-20 2005-12-01 The Scripps Research Institute Transthyretin stabilization
US20050282780A1 (en) * 2004-05-20 2005-12-22 Richard Labaudiniere Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SAVIANA DI GIOVANNI et al. Entacapone and Tolcapone, Two CatecholO-MethyltransferaseInhibitors, Block Fibril Formation of alpha-Synuclein and beta-Amyloid and Protect against Amyloid-induced Toxicity// JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 285, no. 20, 14 May 2010 (2010-05-14), USA, pages 14941 - 14954, XP002690345. KLABUNDE T et al. Rational design of potent human transthyretin amyloid disease inhibitors// NATURE STRUCTURAL BIOLOGY, vol. 7, no. 4, April 2000 (2000-04-01), pages 312 - 321, XP002667711, ISSN: 1072-8368, реферат. *
SAVIANA DI GIOVANNI, SOMINA ELEUTERI, KATERINA E. PALEOLOGOU, GUOWEI YIN, MARKUS ZWECKSTETTER, PIERRE-ALAIN CARRUPT AND HILAL A. L: "Entacapone and Tolcapone, Two CatecholO-MethyltransferaseInhibitors, Block Fibril Formation of alpha-Synuclein and beta-Amyloid and Protect against Amyloid-induced Toxicity", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 285, no. 20, 14 May 2010 (2010-05-14), US, pages 14941 - 14954, XP002690345, ISSN: 0021-9258, DOI: 10.1074/jbc.m109.080390 *

Also Published As

Publication number Publication date
EP2770988B1 (en) 2016-07-20
RU2017119539A (ru) 2018-11-09
KR20140090161A (ko) 2014-07-16
RU2623062C2 (ru) 2017-06-21
CN103889407B (zh) 2017-03-15
US20200138760A1 (en) 2020-05-07
KR102017354B1 (ko) 2019-09-02
BR112014009322B1 (pt) 2022-05-10
NZ623267A (en) 2015-11-27
RU2017119539A3 (OSRAM) 2020-06-29
JP2014530842A (ja) 2014-11-20
WO2013060668A1 (en) 2013-05-02
CY1118151T1 (el) 2017-06-28
CL2014000893A1 (es) 2014-09-05
SG11201401215VA (en) 2014-08-28
US9610270B2 (en) 2017-04-04
IL231907A0 (en) 2014-05-28
CA2852808A1 (en) 2013-05-02
EP2770988A1 (en) 2014-09-03
US20200390733A1 (en) 2020-12-17
BR112014009322A2 (pt) 2017-04-18
US10786473B2 (en) 2020-09-29
HK1198432A1 (en) 2015-04-24
US20170304243A1 (en) 2017-10-26
MX347784B (es) 2017-05-12
US11564899B2 (en) 2023-01-31
BR112014009322A8 (pt) 2018-01-16
MX2014004863A (es) 2014-05-27
AU2012327275B2 (en) 2017-03-02
CN103889407A (zh) 2014-06-25
CA2852808C (en) 2021-07-06
US10449169B2 (en) 2019-10-22
US20140296188A1 (en) 2014-10-02
PL2770988T3 (pl) 2017-01-31
AU2012327275A1 (en) 2014-04-17
PT2770988T (pt) 2016-09-05
SG10201609933WA (en) 2017-02-27
JP6068484B2 (ja) 2017-01-25
RU2014114930A (ru) 2015-12-10
US10045956B2 (en) 2018-08-14
US20190091188A1 (en) 2019-03-28
AU2017202670B2 (en) 2019-06-06
ZA201402546B (en) 2015-07-29
AU2017202670A1 (en) 2017-05-11
AU2012327275A2 (en) 2014-04-17
IL231907B (en) 2018-05-31
ES2593038T3 (es) 2016-12-05
MX385516B (es) 2025-03-18

Similar Documents

Publication Publication Date Title
US11564899B2 (en) Therapy for transthyretin-associated amyloidosis
Bolognin et al. Chelation therapy for neurodegenerative diseases
CA2872012C (en) New methods
EP2397139B1 (en) Anti-neurodegenerative disease agent
EP3065728A1 (en) Novel methods
DE69832695T2 (de) Verwendung von r-enantiomeren nichtsteroidaler entzündungshemmer zur vorbeugung der alzheimerschen krankheit
EP1418910B1 (en) Methods for inhibiting or reversing tau filament formation polymerization
US20210069139A1 (en) Stabilization of transthyretin tetramers in biological fluids
NZ623267B2 (en) New therapy for transthyretin-associated amyloidosis
HK1198432B (en) Therapy for transthyretin-associated amyloidosis
Berkoz The role of oxidative stress in Alzheimer’s disease
HK1208363B (en) Compounds for use in the treatment of aquaporin-mediated diseases